{"id":242967,"date":"2012-02-13T16:47:54","date_gmt":"2012-02-13T16:47:54","guid":{"rendered":"http:\/\/www.eugenesis.com\/bd-acquires-kiestra-lab-automation-bv\/"},"modified":"2012-02-13T16:47:54","modified_gmt":"2012-02-13T16:47:54","slug":"bd-acquires-kiestra-lab-automation-bv","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/microbiology\/bd-acquires-kiestra-lab-automation-bv.php","title":{"rendered":"BD Acquires KIESTRA Lab Automation BV"},"content":{"rendered":"<p><p>    More Topics:               Choose a Sector                    Accounting Firms                    Advertising\/Media\/Communications                    Capital                    CEO\/Board                    General Business                    Health\/Biotech                    Internet\/Technology                    Investment Firms                    Law Firms                    Mergers &amp; Acquisitions                    Money Managers                    People                    Private Companies                    Public Companies                    Venture Capital            <\/p>\n<p>    Posted February 13, 2012  <\/p>\n<p>    Provides Automation Platform to Offer Integrated    Microbiology Lab Solutions  <\/p>\n<p>    FRANKLIN LAKES, N.J. -- BD (Becton, Dickinson    and Company) (NYSE: BDX), a leading global medical technology    company, announced today that it has acquired KIESTRA    Lab Automation BV, a Netherlands-based company that    designs, develops, manufactures, markets and sells innovative    lab automation solutions for the microbiology lab. The    financial terms of the acquisition were not disclosed. The    transaction is expected to be slightly dilutive; however, BD    reaffirms its previous guidance that reported diluted earnings    per share from continuing operations for fiscal year 2012 are    expected to be in the range of $5.60 to $5.70.  <\/p>\n<p>    For further information, read more on BD&#039;s website.  <\/p>\n<p>    About BD  <\/p>\n<p>    BD is a leading global medical technology company that    develops, manufactures and sells medical devices, instrument    systems and reagents. The Company is dedicated to improving    people&#039;s health throughout the world. BD is focused on    improving drug delivery, enhancing the quality and speed of    diagnosing infectious diseases and cancers, and advancing    research, discovery and production of new drugs and vaccines.    BD&#039;s capabilities are instrumental in combating many of the    world&#039;s most pressing diseases. Founded in 1897 and    headquartered in Franklin Lakes, New Jersey, BD employs    approximately 29,000 associates in more than 50 countries    throughout the world. The Company serves healthcare    institutions, life science researchers, clinical laboratories,    the pharmaceutical industry and the general public. For more    information, please visit <a href=\"http:\/\/www.bd.com\" rel=\"nofollow\">http:\/\/www.bd.com<\/a>.  <\/p>\n<p>        <\/p>\n<p>      To find out more about the company in this article and to see      if you<br \/>      have business connections, click below:    <\/p>\n<p>    Please enable JavaScript to view the comments  powered by Disqus. blog comments powered by<\/p>\n<p>Continue reading here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/philly.citybizlist.com\/2\/2012\/2\/13\/BD-Acquires-KIESTRA-Lab-Automation-BV.aspx\" title=\"BD Acquires KIESTRA Lab Automation BV\">BD Acquires KIESTRA Lab Automation BV<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> More Topics: Choose a Sector Accounting Firms Advertising\/Media\/Communications Capital CEO\/Board General Business Health\/Biotech Internet\/Technology Investment Firms Law Firms Mergers &amp; Acquisitions Money Managers People Private Companies Public Companies Venture Capital Posted February 13, 2012 Provides Automation Platform to Offer Integrated Microbiology Lab Solutions FRANKLIN LAKES, N.J.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/microbiology\/bd-acquires-kiestra-lab-automation-bv.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577473],"tags":[],"class_list":["post-242967","post","type-post","status-publish","format-standard","hentry","category-microbiology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/242967"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=242967"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/242967\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=242967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=242967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=242967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}